These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8231461)

  • 41. Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects.
    Weisser K; Schloos J; Lehmann K; Düsing R; Vetter H; Mutschler E
    Eur J Clin Pharmacol; 1991; 40(1):95-9. PubMed ID: 1647954
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Kinetics and dynamics of enalapril in patients with liver cirrhosis.
    Ohnishi A; Tsuboi Y; Ishizaki T; Kubota K; Ohno T; Yoshida H; Kanezaki A; Tanaka T
    Clin Pharmacol Ther; 1989 Jun; 45(6):657-65. PubMed ID: 2543535
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enalapril decreases plasma prolactin levels in hypertensive patients.
    Lombardi C; Missale C; De Cotiis R; Spano PF
    J Biol Regul Homeost Agents; 1989; 3(3):128-30. PubMed ID: 2560316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment.
    Lees KR; Reid JL
    Clin Pharmacol Ther; 1987 Jun; 41(6):597-602. PubMed ID: 3034468
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis.
    Matalka K; Arafat T; Hamad M; Jehanli A
    Fundam Clin Pharmacol; 2002 Jun; 16(3):237-44. PubMed ID: 12165071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the effect of oral enalapril on neutrophil functions: comparison with the in vitro effect of enalapril and enalaprilat.
    Wysocki H; Siminiak T; Zozulińska D; Wierusz-Wysocka B
    Pol J Pharmacol; 1995; 47(1):53-8. PubMed ID: 7550549
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers.
    Zapater P; Novalbos J; Gallego-Sandín S; Hernández FT; Abad-Santos F
    J Cardiovasc Pharmacol; 2004 May; 43(5):737-44. PubMed ID: 15071363
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Angiotensin converting enzyme during acute and chronic enalapril therapy in essential hypertension.
    Jackson B; Johnston CI
    Clin Exp Pharmacol Physiol; 1984; 11(4):355-9. PubMed ID: 6097377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tissue angiotensin converting enzyme inhibition as an index of the disposition of enalapril (MK-421) and metabolite MK-422.
    Cohen ML; Kurz KD; Schenck KW
    J Pharmacol Exp Ther; 1983 Jul; 226(1):192-6. PubMed ID: 6306224
    [No Abstract]   [Full Text] [Related]  

  • 50. Quantification of pulmonary capillary endothelium-bound angiotensin converting enzyme inhibition in man.
    Cziraki A; Horvath I; Rubin JW; Theodorakis M; Catravas JD
    Gen Pharmacol; 2000 Oct; 35(4):213-8. PubMed ID: 11827728
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Slow tight binding inhibitors of angiotensin converting enzyme.
    Ryan JW; Chung AY; Berryer P; Murray MA; Ryan JP
    Adv Exp Med Biol; 1986; 198 Pt A():419-25. PubMed ID: 3028060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of chronic treatment with trandolapril or enalapril on brain ACE activity in spontaneously hypertensive rats.
    Jouquey S; Mathieu MN; Hamon G; Chevillard C
    Neuropharmacology; 1995 Dec; 34(12):1689-92. PubMed ID: 8788966
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Measurement of converting enzyme activity by antibody-trapping of generated angiotensin II. Comparison with two other methods.
    Nussberger J; Brunner D; Keller I; Brunner HR
    Am J Hypertens; 1992 Jun; 5(6 Pt 1):393-8. PubMed ID: 1326287
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radioimmunoassay for the quantitation of lisinopril and enalaprilat.
    Worland PJ; Jarrott B
    J Pharm Sci; 1986 May; 75(5):512-6. PubMed ID: 3016233
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of zinc in vivo and in vitro on the activities of angiotensin converting enzyme and kininase-I in the plasma of rats.
    White CL; Pschorr J; Jacob IC; von Lutterotti N; Dahlheim H
    Biochem Pharmacol; 1986 Aug; 35(15):2489-93. PubMed ID: 3017354
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of enalapril on the in vitro and in vivo peptidyl cleavage of a potent VLA-4 antagonist.
    Karanam BV; Jayraj A; Rabe M; Wang Z; Keohane C; Strauss J; Vincent S
    Xenobiotica; 2007 May; 37(5):487-502. PubMed ID: 17523052
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The relationship between serum enalaprilat concentration and the hypotensive effect in man.
    Ajayi AA; Hockings N; Reid JL
    Int J Clin Pharmacol Res; 1987; 7(1):1-3. PubMed ID: 3034808
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The influence of hydrochlorothiazide on the pharmacokinetics of enalapril in elderly patients.
    Weisser K; Schloos J; Jakob S; Mühlberg W; Platt D; Mutschler E
    Eur J Clin Pharmacol; 1992; 43(2):173-7. PubMed ID: 1330574
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polymorphic inhibition of human angiotensin I-converting enzyme by enalaprilat.
    Lee EJ
    Eur J Clin Pharmacol; 1995; 49(3):173-5. PubMed ID: 8665992
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measurement of angiotensin converting enzyme inhibitors in serum by radioinhibitor binding displacement assay.
    Jackson B; Cubela R; Johnston CI
    Biochem Pharmacol; 1987 Apr; 36(8):1357-60. PubMed ID: 3036166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.